Dare Bioscience, Inc. - 8-K Filing

Daré Bioscience reports Q3 2026 results highlighting commercial progress for Flora Sync LF5 and upcoming dispensing of DARE to PLAY Sildenafil Cream. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $DARE

Read the full article at SEC EDGAR

Part of the story KYNTRA BIO, INC. - 8-K Filing (3 articles)

More Regulatory news